Linked Life Data

2481332

Source:http://linkedlifedata.com/resource/pubmed/id/2481332

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1990-2-8
pubmed:abstractText
In summary, although it is associated with only about a 10% 1-year survival, palliative nephrectomy in the rare patient with symptoms directly referable to the primary tumor is justified to reduce patient suffering. However, non-surgical palliation with renal infarction techniques have been shown to produce effective palliation for the majority of symptoms referable to the primary lesion. In patients with resectable low-volume metastases, a combination of nephrectomy with removal of all visible metastases may be expected to result in a 35% 5-year survival rate with some patients displaying long-term survival. Palliative nephrectomy in patients with non-resectable (high volume) metastases can currently only be recommended for patients in whom adjuvant experimental therapy will be employed in addition to nephrectomy. I believe that these patients should be enrolled in carefully controlled and monitored prospective clinical trials.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0730-9147
pubmed:author
pubmed:issnType
Print
pubmed:volume
7
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-4
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Role of surgery in metastatic renal cell carcinoma.
pubmed:affiliation
Department of Urology, Loyola University Medical Center, Struch School of Medicine, Maywood, IL 60153.
pubmed:publicationType
Journal Article, Review